Compare Johnson & Johnson (JNJ) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Synopsys, Inc. — how do they compare? Johnson & Johnson trades at $261.49 (market cap $618.09B), while Synopsys, Inc. trades at $509.81 (market cap $95.39B). The key difference: Johnson & Johnson is far larger — about 6.5× Synopsys, Inc.'s market cap, and Johnson & Johnson pays a 2.09% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Synopsys, Inc. for 71 Days on average.
| JNJ | SNPS | |
|---|---|---|
Market Cap | $618.09B | $95.39B |
Volume | 6,050,983 | 3,374,903 |
Sector | Health | Technology |
52-Week High | $278.43 | $534.56 |
52-Week Low | $186.00 | $367.70 |
Typical Hold Time | 129 Days | 71 Days |
Enterprise Value | $646.37B | $102.62B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Synopsys (SNPS) stock trades at $505.76, up 0.61% today, near its 52-week high. The technical picture is bullish with strong moving average support, though RSI levels suggest overbought conditions. Fundamentally, the company reported strong quarterly earnings beats and robust revenue growth, driven by AI partnerships with OpenAI and Amazon. Analyst sentiment is overwhelmingly positive with a 93% buy rating and a consensus price target of $572.54, indicating significant upside potential.
The outlook for SNPS is highly favorable, supported by AI-driven demand for chip design software and strategic acquisitions like Ansys. Key risks include high valuation multiples and integration challenges from recent deals. Investors should focus on execution of growth initiatives and monitor competitive pressures in the semiconductor design software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
